BLAINJECTIONINJECTABLE
Approved
Jun 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
NGENLA (somatrogon-ghla) by Pfizer is somatrogon-ghla binds to the gh receptor and initiates a signal transduction cascade culminating in changes in growth and metabolism. Approved for growth hormone deficiency, pituitary dwarfism, idiopathic short stature and 1 more indications. First approved in 2023.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NGENLA (somatrogon-ghla) is a novel recombinant human growth hormone analog approved by the FDA in June 2023 for treating growth hormone deficiency, pituitary dwarfism, idiopathic short stature, and small for gestational age. It works by binding to the GH receptor, activating the STAT5b signaling pathway, and increasing IGF-1 levels to stimulate linear growth and metabolic changes in pediatric patients. Administered via subcutaneous injection, it represents Pfizer's next-generation entry into the established GH replacement market.
Growth
Early-stage growth product with competitive entry into a mature market; product teams are actively scaling commercial infrastructure and field presence.
Mechanism of Action
Somatrogon-ghla binds to the GH receptor and initiates a signal transduction cascade culminating in changes in growth and metabolism. Somatrogon-ghla binding leads to activation of the STAT5b signaling pathway and increases the serum concentration of Insulin-like Growth Factor (IGF-1). GH and IGF-1…
Indications (4)
Worked on NGENLA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.